Trial Profile

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FOG-001 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Tipiracil/trifluridine
Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Parabilis Medicines

30 May 2025 According to a Parabilis Medicines media release, data from this study will be presented at the ASCO Annual Meeting, which begins on May 30 in Chicago, Illinois, and the ESMO Gastrointestinal Cancers Congress 2025, which begins on July 2 in Barcelona, Spain.
25 Jan 2025 Trial design presented at the 2025 Gastrointestinal Cancers Symposium.
23 Jan 2025 According to a Parabilis Medicines media release, Preliminary Phase 1/2 data are expected to be shared publicly in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com